ClinicalTrials.gg
RecruitingNCT03675893Updated Jun 22, 2026

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer

A Phase 2 interventional study of Letrozole and Abemaciclib in Endometrial Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Started Dec 2018; still recruiting 7 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing letrozole in Endometrial Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. Letrozole · Endometrial Neoplasms.

Planned enrollment
2nd of 17
110 · median 53
Started
2018
the only one that year
Phase 2
12 of 17
2 open now
Registered
10th of 17
by date
Lead sponsor
2 of 17
Dana-Farber Cancer Institute

Among the 17 studies testing letrozole in Endometrial Neoplasms, this one is the 2nd largest by planned enrollment, is the only one that started in 2018, is one of 12 in phase 2, and was the 10th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

5 of the 17 studies testing letrozole in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letrozole in Endometrial Neoplasms, or all of them as a file.
02

Study summary

This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer.

The drugs involved in this study are:

  • Abemaciclib (also known as Verzenio™)
  • Letrozole (also known as Femara®)
  • Metformin (also known as Glucophage®)
  • Gedatolisib (also known as PF-05212384)
Read the detailed description

This is a Phase II clinical trial. Phase II clinical trials evaluate whether investigational drugs are effective against a specific disease. "Investigational" means that the drugs are being studied.

The U.S. Food and Drug Administration (FDA) has not approved abemaciclib or letrozole for your specific disease but it has been approved for other uses.

The FDA has approved metformin for diabetes but is considered investigational for its use in cancer.

The FDA has not approved gedatolisib as a treatment for any disease.

Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cancer cell growth. Letrozole is a hormonal therapy that works by lowering the production of estrogen in your body. Estrogen may help to stimulate cancer cells to grow, so lowering the levels of estrogen in your body may work to slow cancer cell growth. Metformin is an antihyperglycemic drug most commonly used to lower the amount of blood sugar in the blood and increase the body's sensitivity to insulin. Metformin also works on cancer cells to stop cancer cell growth and promote cancer cell death. Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor. PAM inhibitors work to stop cancer cell growth. PAM inhibition has been shown to enhance CDK inhibitors and hormonal therapy, like abemaciclib and letrozole.

In this research study, we are hoping to learn whether the combinations of abemaciclib and letrozole alone, or with metformin or gedatolisib are effective at slowing or stopping endometrial cancer cell growth.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Endometrial Cancer
  • CDK4/6
  • ER+
  • Estrogen Receptor
  • PI3K
  • PAM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or histologically confirmed endometrial cancer that is recurrent or and/or resistant to standard therapies, or for which no standard therapy is available. Participants enrolled in the second stage of Cohort 1A, or into Cohort 3, 6 and 7, must have histologically confirmed either i) endometrioid endometrial cancer or ii) endometrial carcinosarcoma with endometrioid epithelial component
  • Participants must have ER-positive disease, defined as ≥ 1 percent of tumor cell nuclei being immunoreactive by immunohistochemistry (IHC). If multiple analyses have been performed, judgment should be based on the most recent or pathology specimen analyzed in a CLIA-certified laboratory.
  • Participants must have , defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam.
  • Age ≥ 18 years
  • performance status of 0 or 1
  • Participants must have normal organ and bone marrow function as defined below:

    • ≥ 1,500/mcL
    • ≥ 100,000/mcL
    • Total ≤ 1.5 × institutional (ULN). Patients with Gilbert's syndrome with a total bilirubin \</= 2.0 times ULN and direct bilirubin within normal limits are permitted.
    • (SGOT)/ALT(SGPT) ≤ 3× institutional ULN
    • Creatinine ≤ 1.5 × institutional ULN, OR
    • ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
  • For cohorts 6 and 7, patients must not have remaining ovarian function to be included. Women who have ovarian function are eligible but must be placed on hormonal suppression.
  • The effects of the study agents on the developing human fetus are unknown. For this reason, women of must agree to use a medically approved method during the treatment period and for 3 months following the last dose of study agent. Contraceptive methods may include an intrauterine device (IUD) or barrier method. If condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. A negative serum pregnancy test is required for study entry from women of childbearing potential.
  • Ability to understand and the willingness to sign a written document.
  • Ability to swallow and retain oral medication.
  • Participants can have received an unlimited number of prior therapies.
  • Participants must have archival tissue available for analysis in the form of a formalin-fixed paraffin embedded (FFPE) block or unstained slides. Note: confirmation of availability of archival tissue is the only requirement for eligibility, archival tissue does not need to be received by the study team prior to enrollment
  • For Cohorts 6 and 7, participants must have ≤6.4% and fasting plasma glucose (FPG) ≤140 mg/dL.
  • For Cohort 6 and 7, patients must have wildtype TP53 as assessed either by immunohistochemistry or any CLIA-certified next-generation sequencing assay.
  • For Cohort 7, patients must have received prior CDK4/6 inhibitor therapy and developed disease progression as deemed by the investigator. Patients who have stopped CDK4/6 inhibitor therapy because of intolerance are ineligible.

Exclusion criteria

Exclusion Criteria:

  • Participants who have had chemotherapy, immune therapy, other therapy, or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first dose of study medication. Previous hormonal therapy, including prior letrozole, is allowed and there is no required for hormonal therapy.
  • Participants who have had tyrosine kinase inhibitor (TKI) therapy within 5 half-lives of study entry.
  • Participants who have had radiation therapy within 2 weeks of the first dose of study medication.
  • Participants who have received previous treatment with CDK4/6 inhibitors, including but not limited to previous abemaciclib therapy. For Cohort 7, patients must have received prior treatment with CDK4/6 inhibitors.
  • Participants who are currently receiving metformin therapy (if enrolling to Cohort 3).
  • Participants who have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs
  • Participants with known should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents that the participant will be administered.
  • Participants who at the time of study enrollment are known to require concomitant therapy with moderate or strong inducers, or strong inhibitors of CYP3A4. Due to potential drug interactions, concomitant use of these medications is not permitted for the duration of treatment on trial. Participants are eligible for study entry if an appropriate substitution is made prior to the first dose of study medication.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Use of known -prolonging drugs during screening or expected requirement for use during study therapy.
  • Participants with histories or evidence of cardiovascular risk including any of the following: acute coronary syndromes (i.e. myocardial infarction or angina), coronary angioplasty, or stenting within 6 months prior to study enrollment.
  • Pregnant women are excluded from this study because the study agents are anti-cancer agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding must be discontinued if the mother is treated on trial.
  • Individuals with a history of a different are ineligible with the following exceptions: individuals who have been treated and are disease-free for a minimum of 5 years prior to study enrollment, or individuals who are deemed by the treating investigator to be at low risk for disease recurrence. Additionally, individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: basal or squamous cell carcinomas of the skin, and breast or cervical carcinomas in situ.
  • Known -positive participants are ineligible because of the increased risk of lethal infections when treated with marrow-suppressive therapy.
  • Participants with a history of uncontrolled hypertension despite optimal medical management, defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 90 mmHg.
  • For Cohorts 6 and 7: Inability to determine the corrected QT interval using Fridericia's formula (QTcF) on the (i.e., unreadable or not interpretable) or QTcF>480 msec (determined by mean of triplicate ECGs at screening).
  • For Cohorts 6 and 7, participants with type 1 diabetes or uncontrolled type 2 diabetes.
  • For Cohorts 6 and 7, participants who have previously received any PI3K pathway inhibitors are ineligible. Up to 10 patients in Cohort 6 and up to 10 patients in Cohort 7 may have received prior mTOR inhibitor therapy such as everolimus.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    * Abemaciclib is administered by mouth twice daily * LY3023414 is administered by mouth twice daily * Letrozole is administered by mouth once daily

    Drug: Letrozole · Drug: Abemaciclib · Drug: LY3023414

  • Experimental
    Cohort 2

    * Abemaciclib is administered by mouth twice daily * LY3023414 is administered by mouth twice daily

    Drug: Abemaciclib · Drug: LY3023414

  • Experimental
    Cohort 1A

    * Abemaciclib is administered by mouth twice daily * Letrozole is administered by mouth once daily

    Drug: Letrozole · Drug: Abemaciclib

  • Experimental
    Cohort 3

    * Abemaciclib is administered by mouth twice daily * Letrozole is administered by mouth once daily * Metformin is administered by mouth once daily

    Drug: Letrozole · Drug: Abemaciclib · Drug: Metformin

  • Experimental
    Cohort 6

    * Abemaciclib is administered by mouth twice daily * Letrozole is administered by mouth once daily * Gedatolisib is administered intravenously on days 1, 8 and 15 of a 28-day cycle

    Drug: Letrozole · Drug: Abemaciclib · Drug: Gedatolisib

  • Experimental
    Cohort 7

    * Abemaciclib is administered by mouth twice daily * Letrozole is administered by mouth once daily * Gedatolisib is administered intravenously on days 1, 8 and 15 of a 28-day cycle

    Drug: Letrozole · Drug: Abemaciclib · Drug: Gedatolisib

Interventions

  • Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

    Also known as: Femara

  • Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.

    Also known as: Verzenio

  • LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.

  • Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.

    Also known as: Glucophage

  • Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor.

    Also known as: PF-05212384

06

What researchers measure

Primary outcomes

  1. Progression Free Survival Rate

    Number of patients alive and disease progression-free per RECIST 1.1 criteria.

    Time frame: 6 months

  2. Objective Tumor Response Rate

    Number of patients who experience objective tumor responses per RECIST 1.1 criteria.

    Time frame: 6 months

Secondary outcomes

  1. Overall Survival Rate

    Length of time from study enrollment to death from any cause.

    Time frame: 3 years

  2. Treatment-related toxicities

    Toxicities measured by CTCAE version 5.0 criteria.

    Time frame: 3 years

07

Study locations

3 of 3 sites recruiting
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02214, United States
    Recruiting
    • Cesar Castro, MD · Contact617-724-4000
    • Cesar Castro, MD · Principal investigator
  • Beth Israel Deaconess Medical Center (BIDMC)
    Boston, Massachusetts 02215, United States
    Recruiting
    • Page Widick, MD · Contact(617) 667-5661
    • Page Widick, MD · Principal investigator
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
08

References and documents

Publications

  • Konstantinopoulos PA, Lee EK, Xiong N, Krasner C, Campos S, Kolin DL, Liu JF, Horowitz N, Wright AA, Bouberhan S, Penson RT, Yeku O, Bowes B, Needham H, Hayes M, Sawyer H, Polak M, Shea M, Cheng SC, Castro C, Matulonis UA. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. J Clin Oncol. 2023 Jan 20;41(3):599-608. doi: 10.1200/JCO.22.00628. Epub 2022 Sep 29. PubMed 36174113 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Aug 2028, 115 months after the start.

Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's planned 115 months is above that.

Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2018
First posted
Sep 18, 2018
StartActual
Dec 24, 2018
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2031
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03675893
Collaborators
Eli Lilly and Company, Celcuity Inc
Responsible party
Panagiotis Konstantinopoulos, MD, PhD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Sep 18, 2018
Start date
Dec 24, 2018
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2031 (estimated)
Last update
Jun 22, 2026

Study contacts

Panagiotis Konstantinopoulos, MD
Contact
PanagiotisA_Konstantinopoulos@DFCI.HARVARD.EDU
877-338-7425
Panagiotis Konstantininopoulos, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Letrozole · Abemaciclib · Metformin · Gedatolisib

Start the discussion